copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
2022 ACC Expert Consensus Decision Pathway on the Role of . . . The CLEAR Tranquility (Evaluation of the Efficacy and Safety of Bempedoic Acid [ETC-1002] as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C) and CLEAR Serenity (Evaluation of the Efficacy and Safety of Bempedoic Acid in Patients With Hyperlipidemia and Statin Intolerant) trials have demonstrated that monotherapy with bempedoic acid
Bempedoic Acid: A New Tool for LDL-Cholesterol Control in . . . Abstract Nowdays a small proportion of patients with high very high extreme atherosclerotic cardiovascular disease risk achieves the optimal target of LDL-cholesterol, because of drug intolerance, poor adherence to the therapy, or inapplicability of the stepwise strategy in lipid lowering therapy, recommended by the current guidelines The new oral agent bempedoic acid lowers plasma LDL
Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . . In addition, bempedoic acid and statin combination therapy can be used for patients sensitive to high statin doses 6 Diagram of how bempedoic acid inhibits cholesterol synthesis within the liver Adapted from Rusisca et al
Stepwise Approach to Novel Lipid-Lowering Medications The article reviews the efficacy and safety of novel lipid-lowering agents, i e , proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, bempedoic acid, icosapent ethyl, evinacumab, and lomitapide The latter two are indicated for management of homozygous familial hypercholesterolemia
Bempedoic acid in the management of lipid disorders and . . . Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
PATIENT-CENTERED EDUCATION FROM THE NATIONAL LIPID . . . Bempedoic acid interferes with an enzyme in the liver that regulates cholesterol production It allows for increased clearance of LDL-C from the blood stream leading to lower levels Bempedoic acid is only active within the liver cells and not in skeletal muscle Therefore, it can be used in patients who have had prior statin associated muscle symptoms
Bempedoic Acid: A Novel LDL Cholesterol–Lowering Agent Bempedoic acid is an attractive adjunctive therapy for LDL cholesterol–lowering in adults Additionally, its design helps to avoid myalgia risk, and its oral administration makes it potentially easier to use than injectable PSCK9 inhibitors
(PDF) Bempedoic Acid: A Novel Approach in Managing . . . This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with
Comprehensive review of statin-intolerance and the practical . . . Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17–28 % in SI